NOVAVAX INC Cash Flow Statement
NVAX / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
NOVAVAX INC used $245M in operating cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.87 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.5%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $440.3M | -$187.5M | -$545.1M | -$418.3M | -$1.7B | -$418.3M | -$183.8M | -$280.0M | -$156.9M | -$82.9M | -$52.0M | -$28.5M | -$52.0M | -$35.7M | -$19.4M |
| Depreciation & Amortization | $28.0M | $48.0M | $41.0M | $4.3M | $13.0M | $4.3M | $7.6M | $7.7M | $5.1M | $4.4M | $2.6M | $1.7M | $2.6M | $1.4M | $1.6M |
| Operating Cash Flow | -$244.6M | -$87.3M | -$714.0M | -$42.5M | $322.9M | -$42.5M | -$144.5M | -$258.8M | -$126.1M | -$67.0M | -$45.4M | -$18.2M | -$45.4M | -$32.9M | -$23.6M |
| Capital Expenditures | - | - | - | $54.5M | $57.5M | $54.6M | $4.2M | $18.2M | $18.3M | $7.3M | $5.8M | $4.3M | $5.8M | $1.6M | $610.0K |
| Free Cash Flow | - | - | - | -$97.0M | $265.5M | -$97.2M | -$148.7M | -$277.0M | -$144.4M | -$74.3M | -$51.1M | -$22.6M | -$51.1M | -$34.4M | -$24.2M |
| FCF Margin | - | - | - | -20.4% | 23.2% | -20.4% | -476.9% | -1804.0% | -398.2% | -242.3% | -244.5% | -102.2% | -244.5% | -10031.5% | - |